WHAT IS CLAIMED IS:

1. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing a polybacterial infection in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *Staphylococcus aureus* (*S. aureus*) antigen is to be administered to the patient, wherein the polybacterial infection comprises *S. aureus* and at least one other bacterium.

2. The use of claim 1, wherein the *S. aureus* potentiates the growth of the at least one other bacterium in the patient.

3. The use of claim 1 or 2, wherein the administration inhibits the growth of the at least one other bacterium.

4. The use of any one of claims 1-3, wherein the at least one other bacterium is *Pseudomonas*, *Klebsiella* or *Acinetobacter*.

5. The use of claim 4, wherein the *Pseudomonas* is *Pseudomonas aeruginosa* (*P. aeruginosa*), the *Klebsiella* is *Klebsiella pneumonia*e (*K. pneumoniae*) or the *Acinetobacter* is *Acinetobacter baumannii* (*A. baumannii*).

6. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing a polybacterial infection in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *P. aeruginosa* antigen is to be administered to the patient, wherein the polybacterial infections comprises *P. aeruginosa* and at least one other bacterium.

7. The use of claim 6, wherein the *P. aeruginosa* potentiates the growth of the at least one other bacterium in the patient.

8. The use of claim 6 or 7, wherein the administration inhibits the growth of the at least one other bacterium.

9. The use of any one of claims 6-8, wherein the at least one other bacterium is *Staphylococcus, Klebsiella* or *Acinetobacter*.

10. The use of claim 9, wherein the at least one other bacterium is *S. aureus, K. pneumoniae* or *A. baumannii*.

11. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting the growth of *P. aeruginosa* in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *S. aureus* antigen is to be administered to the patient.

12. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for reducing *S. aureus* colony forming units (CFU) in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *Pseudomonas aeruginosa* antigen is to be administered to the patient.

13. The use of any one of claims 1-5 or 11, wherein the *S. aureus* antigen is alpha toxin.

14. The use of claim 13, wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs:20 and 19; SEQ ID NOs; 22 and 21; SEQ ID NOs:24 and 23; SEQ ID NOs:26 and 25; SEQ ID NOs:28 and 27; SEQ ID NOs:29 and 30; SEQ ID NOs:31 and 32; SEQ ID NOs:33 and 34; SEQ ID NOs:35 and 36; SEQ ID NOs:37 and 38; SEQ ID NOs:39 and 40; SEQ ID NOs:41 and 42; SEQ ID NOs:43 and 44; SEQ ID NOs:45 and 46; SEQ ID NOs:47 and 48; SEQ ID NOs:49 and 46; SEQ ID NOs:50 and 46; SEQ ID NOs:50 and 51; or SEQ ID NOs:67 and 51.

15. The use of claim 13, wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin is an antibody or antigen-binding fragment thereof comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:7, 10, 13, or 57; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:8, 11, 14, 17, 58 or 63; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:9, 12, 15, 18, 16, 53, 54, 55, 66, 59, 60 or 64; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:1 or 4; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:2, 5, 61 or 65; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:3, 6, 52, 56 or 62.

16. The use of claim 13, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs:7, 8, 9, 1, 2 and 3; SEQ ID NOs:10, 11, 12, 1, 2 and 3; SEQ ID NOs:13, 14, 15, 4, 5 and 6; SEQ ID NOs:7, 17, 18, 1, 2 and 3; SEQ ID NOs:7, 8, 16, 1, 2 and 52; SEQ ID NOs:7, 8, 53, 1, 2 and 52; SEQ ID NOs; 7, 8, 54, 1, 2 and 52; SEQ ID NOs:7, 8, 55, 1, 2 and 56; SEQ ID NOs:7, 8, 55, 1, 2 and 52; SEQ ID NOs:7, 8, 66, 1, 2 and 52; SEQ ID NOs:7, 8, 53, 1, 2 and 56; SEQ ID NOs:57, 58, 59, 1, 2 and 56; SEQ ID NOs:7, 8, 60, 1, 61 and 62; SEQ ID NOs:57, 63, 59, 1, 2 and 56; SEQ ID NOs:57, 63, 64, 1, 2 and 56; SEQ ID NOs:57, 63, 64, 1, 65 and 62; or SEQ ID NOs:57, 58, 59, 1, 65 and 67.

17. The use of claim 13, wherein antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs:45 and 46.

18. The use of any one of claims 6-10 or 12, wherein the *P. aeruginosa* antigen is Psl, PcrV, or both Psl and PcrV.

19. The use of claim 18, wherein the antibody or antigen-binding fragment thereof binds to *P. aeruginosa* Psl and PcrV.

20. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3

sequences of SEQ ID NOs:73, 74, 80, 76, 77, and 78 or SEQ ID NOs: 73, 74, 94, 76, 77, and 95.

21. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs:83, 84, 85, 86, 87, and 88.

22. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH sequence of SEQ ID NO:79 and the VL sequence of SEQ ID NO:72.

23. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH sequence of SEQ ID NO:81 and the VL sequence of SEQ ID NO:82.

24. The use of any one of claims 1-10, wherein the polybacterial infection is an ocular infection, a lung infection, a burn infection, a wound infection, a surgical wound infection, a skin infection, a soft tissue infection, a blood infection, a bone infection, or a combination of two or more of said infections.

25. The use of any one of claims 1-24, wherein the patient has acute pneumonia, burn injury, corneal infection, cystic fibrosis, ventilator-associated pneumonia, a skin infection, a wound infection, or a combination thereof.